Aurinia Pharmaceuticals to Present at Three Upcoming March Investor Conferences

Rhea-AI Summary

Aurinia Pharmaceuticals (NASDAQ: AUPH) announced participation in three upcoming investor conferences. The events include the Cowen 41^st Annual Healthcare Conference on March 4, 2021, at 2:10 p.m. ET, the H.C. Wainwright Global Life Sciences Conference on March 9, 2021, at 7:00 a.m. ET, and the Oppenheimer’s 31^st Annual Healthcare Conference on March 17, 2021, at 10:40 a.m. ET. Interested investors can access the live webcasts through the 'Investors' section on Aurinia's website. Aurinia specializes in therapies for serious diseases, notably the FDA-approved LUPKYNIS™ for lupus nephritis.

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the executive management team will participate in multiple upcoming investor conferences including the:

• Cowen 41^st Annual virtual Healthcare Conference fireside chat on Thursday, March 4, 2021 at 2:10 p.m. ET;
• H.C. Wainwright Global Life Sciences Conference fireside chat available on Tuesday, March 9, 2021 at 7:00 a.m. ET; and
• Oppenheimer’s 31^st Annual Healthcare Conference presentation on Wednesday, March 17, 2021 at 10:40 a.m. ET.

In order to participate in the audio webcast, interested parties can access the live webcast under "News/Events” through the “Investors” section of the Aurinia corporate website at www.auriniapharma.com. A replay of the webcast will be available on Aurinia’s website.

ABOUT AURINIA

Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The Company has introduced LUPKYNIS™ (voclosporin), the first FDA-approved oral therapy dedicated for the treatment of adult patients with active lupus nephritis (LN). The Company’s head office is in Victoria, British Columbia, its U.S. commercial hub is in Rockville, Maryland, and the Company focuses its development efforts globally.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210302005227/en/

FAQ

When is Aurinia's participation in the Cowen 41st Annual Healthcare Conference?

Aurinia will participate in the Cowen 41st Annual Healthcare Conference on March 4, 2021, at 2:10 p.m. ET.

What time will Aurinia present at the H.C. Wainwright Global Life Sciences Conference?

Aurinia's presentation at the H.C. Wainwright Global Life Sciences Conference is scheduled for March 9, 2021, at 7:00 a.m. ET.

When is the Oppenheimer’s 31st Annual Healthcare Conference for Aurinia?

Aurinia will present at Oppenheimer’s 31st Annual Healthcare Conference on March 17, 2021, at 10:40 a.m. ET.

How can I access Aurinia's investor conference webcasts?

You can access Aurinia's investor conference webcasts through the 'Investors' section on their corporate website.

What is LUPKYNIS™ and its approval status?

LUPKYNIS™ (voclosporin) is the first FDA-approved oral therapy for adult patients with active lupus nephritis.